ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Sep 27, 2018
HCA Healthcare - Building Out a Healthcare Network
Image Source: HCA second-quarter 2018 Investor Update. We are becoming increasingly intrigued by the consolidation occurring in the hospital sector as HCA Healthcare is well on its way to developing a dominant position in some of the more populated states in the US.
Sep 6, 2018
In the News: Musk, Facebook, and GameStop
We’re not sure that Tesla has things figured out. Social media entities, including one of our favorites Facebook, have fallen on hard times given negative sentiment. GameStop could sell itself for a significantly higher price than what the market is currently willing to exchange shares.
Sep 5, 2018
In The News: APU, EPD, MMP, OHI, PSA, O, TGE
We’re keeping a close eye on a number of high-yielding equities, and several have reported strong earnings during the calendar second quarter.
Aug 31, 2018
Stellar Keytruda Growth Powers Merck Higher
Shares of pharmaceutical giant Merck continue to accelerate thanks in large part to the growth of its key oncology asset Keytruda. Even though Merck is a well-established entity, future growth is highly correlated to the continued expansion of Keytruda as it continues to gain market share thanks in large part to superior clinical data and label expansion.
Aug 23, 2018
Pfizer: Lots of Moving Parts in a Generally-Inspiring Second Quarter
Image Source: Pfizer. We came away generally impressed with the progress at Pfizer during the second quarter as the company begins to replace its current patent protected line-up with next-generation treatments. Pfizer continues to gain political favor with its decision to forgo price hikes on its product line-up while announcing a re-organization of the business structure.
Aug 17, 2018
ICYMI -- Podcast: 2nd Annual Nelson Exclusive Yearly Round Up Call
President of Investment Research at Valuentum Brian Nelson talks the markets, valuations, the economy, the consumer and various other trends from crude oil to cryptocurrency to geopolitical risks to corporate tax reform and beyond. Running time ~25 minutes.
Aug 7, 2018
Gilead Sciences at the Crossroads
We continue to be big fans of the transformation currently underway at Gilead Sciences. That said, however, we were initially surprised by CEO John Milligan’s decision to step down.
Jul 27, 2018
Dividend Increases/Decreases for the Week Ending July 27
We provide a list of firms that raised/lowered their dividends during the week ending July 27. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header.
Jul 23, 2018
Hasbro Shares Jump Despite Transient Challenges
Image Source: William Warby. Simulated Dividend Growth Newsletter idea Hasbro turned in another lackluster quarterly report, but its second-quarter results were better than expected as the company continues to work through a variety of what it believes are transient issues.
Jul 20, 2018
Dividend Increases/Decreases for the Week Ending July 20
We provide a list of firms that raised/lowered their dividends during the week ending July 20. The dividend reports of covered firms on this list will be updated shortly with the new information. To access our dividend reports use the ‘Symbol’ search box in our website header.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.